Annals of the Rheumatic Diseases
Volume 72, Issue 9
Enzymes, Immobilized--adverse effects; Gout--drug therapy; Gout Suppressants--adverse effects; Polyethylene Glycols--adverse effects; Urate Oxidase--adverse effects
Objective: To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in patients with refractory chronic gout.
Methods: This open-label extension (OLE) study was conducted at 46 sites in the USA, Canada and Mexico. Patients completing either of two replicate randomised placebo-controlled 6-month trials received pegloticase 8 mg every 2 weeks (biweekly) or every 4 weeks (monthly). Safety was evaluated as the primary outcome, with special interest in gout flares and infusion-related reactions (IRs). Secondary outcomes included urate-lowering and clinical efficacy.
Results: Patients (n=149) received a mean±SD of 28±18 pegloticase infusions and were followed for a mean of 25±11 months. Gout flares and IRs were the most frequently reported adverse events; these were least common in patients with a sustained urate-lowering response to treatment and those receiving biweekly treatment. In 10 of the 11 patients with a serious IR, the event occurred when uric acid exceeded 6 mg/dl. Plasma and serum uric acid levels remained <6 mg/dl in most randomised controlled trial (RCT)-defined pegloticase responders throughout the OLE study and were accompanied by sustained and progressive improvements in tophus resolution and flare incidence.
Conclusions: The safety profile of long-term pegloticase treatment was consistent with that observed during 6 months of RCT treatment; no new safety signals were identified. Improvements in clinical status, in the form of flare and tophus reduction initiated during RCT pegloticase treatment in patients maintaining goal range urate-lowering responses were sustained or advanced during up to 2.5 years of additional treatment.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Becker, M.A., Baraf, H.S., Yood, R.A., Dillon, A., Vazquez-Mellado, J. et al. (2013). Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Annals of the Rheumatic Diseases, 72(9), 1469-1474.